Generics win anti-pay-for-delay bill challenge

The Association for Accessible Medicines (AAM), which represents manufacturers of generics and biosimilars, has succeeded in challenging a California bill that characterises “reverse payment” or “pay-for-delay” patent settlements as anticompetitive and unlawful.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Judge partially revives California pay-for-delay ban

17 February 2022 A Californian judge has partially revived the state’s pay-for-delay ban after attorney general Rob Bonta requested that a preliminary injunction against the ban be modified.

article

FTC insists generics ANI and Novitium divest IP before merger

11 November 2021 The Federal Trade Commission has stipulated that generic drug marketers ANI Pharmaceuticals, and Novitium Pharma must divest IP rights to Prasco ahead of their $210 million merger.

Generics

Teva sues two Indian generics over Huntington’s treatment

6 July 2021 Teva Pharmaceuticals has filed lawsuits in New Jersey against two Indian generics manufacturers to stop them from developing a generic version of its Huntington’s disease treatment.

More features

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Generics win anti-pay-for-delay bill challenge

More on this story

Editor's picks

Editor's picks

More features